CFTR modulators have significantly slowed the progression of cystic fibrosis (CF), but fail to reverse established lung damage, leaving chronic infections and inflammation unresolved. Moreover, by reducing sputum production, these therapies make it more difficult to detect infections and inflammation in a timely and accurate manner. This highlights the need for new, simple, and non-invasive methods to monitor lung infections, enabling earlier diagnosis and more effective, personalized treatment strategies aligned with the evolving clinical profile of CF. This project takes an innovative approach by looking beyond the lungs to explore the gut–lung connection in CF. Researchers will analyze fecal samples from people with CF—easy to collect from anyone, including those who no longer produce sputum—to detect respiratory pathogens such as Pseudomonas aeruginosa, one of the main pathogens responsible for respiratory infections in CF. These results will be compared with findings from sputum, throat swabs, and oropharyngeal aspirates to determine whether the same pathogens are present in both the gut and respiratory tract.  The ultimate goal is to develop a simple, reliable, and non-invasive method for early detection of lung infections, particularly in individuals with CF who produce little or no sputum. In the long term, this approach could transform screening practices, allowing for more personalized treatments and improving both clinical outcomes and quality of life for people with CF.